Here are the DEF 14A proxy statements from Quest Diagnostics Inc. (DGX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow DGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DGX filings page.
Quest Diagnostics is asking stockholders to vote at its 2026 annual meeting on electing eleven directors, approving 2025 executive pay on an advisory basis, ratifying its auditor, and a stockholder proposal for an independent board chair.
The proxy details a pay-for-performance program where about 92% of CEO target compensation and 81% for other named executives is variable. In 2025, net revenues were $11.04B, diluted EPS was $8.75 (adjusted $9.85), and average annual incentive payouts were 116% of target, with performance shares paying out at 154% of target. The company reports 1‑, 3‑, and 5‑year total shareholder returns of 17.2%, 17.8%, and 60.7%, respectively, and highlights continued dividend growth and share repurchases.